Introduction: This study evaluated prevalence and predictors of osteoporosis and sarcopaenia in men with HIV. Material and methods: A total of 220 men with HIV were screened, of which 115 men, 30-50 years-age, having at least one-year followup, underwent hormonal and DEXA analysis. Forty controls were also evaluated. Results: Males with HIV had significantly lower BMD and Z-scores at all sites. Osteoporosis was diagnosed in 64.35%, the commonest site being radius total (49.56%), followed by radius 33% (45.21%), radius ultra distal (36.52%), lumbar spine (19.13%), neck of femur (17.39%), and total femur and greater trochanter (7.82% each). HIV patients had significantly lower fat mass (FM), lean mass (LM), total fat percentage, bone mineral content, gynoid fat, and percentage skeletal muscle mass (PSMM). Men with osteoporosis had higher use of anti-retroviral therapy (ART), immune reconstitution inflammatory syndrome (IRIS), tuberculosis, and lower FM, LM, and PSMM. Logistic regression revealed that PSMM, age, and delta (Δ) CD4 count (change in CD4 count after 6-12 months of ART, compared to pre-ART) were the best predictors of osteoporosis. Greater PSMM was associated with decreased osteoporosis, without adjusting for any variable (Model-1), adjusting for disease duration, tuberculosis and IRIS (Model-2), and model-2 plus gonadotropins and sex steroids (Model-3). Greater ΔCD4 count and age were associated with increased osteoporosis after adjusting for different models. Sarcopaenia was observed in 40% of men and in none of the controls. Conclusions: Men with decreased skeletal mass, age, severe immune dysfunction at diagnosis, having rapid increase in CD4 count following ART and IRIS have higher risk of osteoporosis in the long run. (Endokrynol Pol 2017; 68 (6): 642-651)
Introduction
With the increasing burden of the HIV epidemic, coupled with better outcomes, endocrinopathies are increasingly being encountered in HIV patients [1] . Endocrinopathies are commonly associated with impaired bone health [2, 3] . In a meta-analysis, patients with HIV had three-times higher prevalence of low bone mineral density (BMD), compared to controls [4] . Globally, high prevalence of vitamin-D deficiency has been observed in patients with HIV [5, 6] . Most of the global data on BMD in HIV is available from males, predominantly Caucasians [7] . Most of these studies are limited by a lack of evaluation of representative controls [7] .
Alterations in body composition are known to have an impact on bone health in non-HIV infected individuals [8] . A variety of patterns of alterations in lean mass (LM), fat mass (FM), and bone mineral content (BMC) have been reported in HIV [9] . However, bone health and body composition alterations among Indians with HIV has not been evaluated. Hence this study aimed to assess the burden of low BMD (osteoporosis) and determine its predictors in asymptomatic young men with HIV infection.
Material and methods
The anti-retroviral therapy (ART) clinic at our centre is an apex referral centre, functional since April 2004, established by the National AIDS Control Organisation (NACO) of India and the World Health Organisation (WHO) [1] . Consecutive ambulatory males, 30-50 years of age, with serologically documented HIV infection, in stable clinical condition, without any acute, severe illness, attending the ART clinic, were considered. Men above 30 years of age were only considered for this study because peak bone mass is usually reached by 29 years of age [2] . Also, patients above 50 years of age were excluded to eliminate patients with senile/ /age-related bone loss. Severely ill patients with multiple co-morbid states, which would warrant hospital admission, patients with known endocrinopathies (hypogonadism, hypopituitarism, hypothyroidism, hypocortisolism) were excluded. Patients with a history of hospital admissions in the preceding two months were also excluded. Patient records were reviewed, and those having clinical data of at least one-year followup were further evaluated. Patients with available CD4 cell counts at diagnosis (pre-HAART) and at first follow-up (6-12 months after diagnosis) were included. The study protocol was explained, and only those who gave informed, written consent were included. The institutional Ethics Committee approved the study protocol. The period of study was from August 2015 until December 2016.
Data were collected regarding duration of HIV infection and details of highly active anti-retroviral therapy (HAART). Data was also collected regarding past or current evidence of opportunistic infections (bacterial, viral, and fungal). Patients underwent detailed clinical assessment, including anthropometry. Patients were called on subsequent days in fasting state for blood sampling. Blood samples of 5 ml each were collected in plain and EDTA vacutainers (Becton Dickinson). Serum was separated from the blood collected in plain vacutainers and processed immediately for routine biochemical analysis, and one aliquot of serum was stored at -20°C for specific immunological (hormonal) assays. The EDTA sample was processed for haematological analysis.
Chemiluminescent microparticle immunoassay (VITROS® ECiQ Immunodiagnostic System, Johnson & Johnson, USA) was used for estimation of 25-hydroxyvitamin-D (25OHD), prolactin, testosterone, luteinising hormone (LH), and follicle stimulating hormone (FSH). Serum 25OHD assay had an analytical sensitivity of 19.97 nmol/L, analytical range of 19.97-374.40 nmol/L, and intra and inter-assay coefficient of variation (CV) of 3.4% and 5.5%, respectively. Testosterone assay had analytical sensitivity of 0.16 mcg/dl, analytical range of 0.17-75.06 nmol/L, and intra and inter-assay CV of 3.8% and 7.4%, respectively. LH assay had analytical sensitivity of 0.216 IU/L, analytical range of 0.216-200 IU/L, and intra and inter-assay CV of 8.8% and 11.3%, respectively. FSH assay had analytical sensitivity of 0.66 IU/L, analytical range of 0.66-200 IU/L, and intra and inter-assay CV of 2.8% and 10.1%, respectively. Serum calcium, phosphate, alkaline phosphate, and renal function tests were done using clinical chemistry auto-analyser based on dry chemistry micro-slide technology (VITROS® 350 chemistry system, Johnson & Johnson, USA). CD4 cell count was performed using flow cytometry (Becton Dickinson Immunocytochemistry Systems, San Jose, CA).
All patients underwent BMD assessment by dualenergy X-ray absorptiometry (DEXA; Discovery Wi Series, Serial Number: 84571; Hologic Inc., Waltham, MA) at lumbar spine (LS, L1-L4 anteroposterior), left proximal femur [neck (NOF), greater trochanter (GT) and total femur (TF)], and left forearm regions [radius 33%, ultra-distal (UD) and radius total]. Quality control procedures were done as per manufacturer 's recommendations. A trained technician in the department performed all scans. The instrument was calibrated on a daily basis, using phantom provided by the manufacturer, and the CV at different sites was found to be < 1.0% over the duration of the study. The manufacturer 's appointed service engineer reviewed the calibration data and performed a scanner maintenance check to ensure the system's performance before, at the beginning, and at the end of the study to confirm that no instrumentation drift occurred during the study period. The BMD of the subjects was recorded in terms of absolute mineral content (in g/cm 2 ) at various sites. Due to significant differences in the ages of patients in the study (30-50 years), Z-score [number of standard deviations (SD) away from average value of age and gender specific reference group] was used to compare BMD across the groups. Osteoporosis at any site was diagnosed if Z-score was < -2 SD [10] . T-score was not used for defining osteoporosis because it has been established for diagnosis of osteoporosis in the female postmenopausal state [8] .
DEXA was also used for estimation of whole-body bone mineral content (BMC) (kg), total body fat (kg), percentage fat mass (%), fat mass (FM) (kg), lean mass (LM) (kg), android fat (kg), and gynoid fat (kg). Body composition analyses of soft tissues were performed using QDR2000 product software, version 7.10A (Hologic). The lower border of the android region was set at upper border of pelvis. The upper border of the android region was set at a level being 20% of the distance from the upper border of the pelvis to the neck. The upper border of the gynoid region was set at the level below the upper border of the pelvis at a distance of 1.5 times the length of the android region. The lower border of the gynoid region was set at the level at which the length of the gynoid region was twice the length of the android region [1, 11] . The reproducibility of DEXA measurements was derived from the root mean square standard deviation of two repeat measurements [1, 11] . The technique precision for body composition variables was 12.32 g for BMC (0.96% CV), 166.3 g for LM (0.74% CV), and 156.2 g for FM (0.72% CV). Clinical, biochemical, and DEXA parameters were also collected from 40 age-, sex-, and BMI-matched healthy controls, recruited from the nursing staff of the institute, who had given informed written consent.
Sarcopaenia has been defined as progressive and generalised loss of skeletal muscle mass and strength, associated with increased morbidity and mortality [12] . Documenting low muscle mass is an important component of assessing sarcopaenia. The percentage of skeletal muscle mass (PSMM) (total lean mass/weight x 100) was calculated in patients and controls [12] . Low skeletal mass volume (PSMM) has been used to define sarcopaenia [12] . Due to lack of normative date from the India population, according to the European Working Group on Sarcopaenia in Older People recommendations, a PSMM of < 2 SD below the mean in the healthy control group was used to define sarcopaenia [13] . Studies have shown that PSMM provides a better and higher estimation of sarcopaenia when DEXA is used as a tool for assessment [12, 13] .
Immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients is characterised by clinical deterioration secondary to re-establishment of immunity following HAART [14] . It is usually observed in patients with low baseline CD4 count, which increases rapidly following HAART initiation. HAART has been linked to increased systemic inflammation and autoimmunity [14, 15] . IRIS has been defined as CD4 count > 200 cells/mm 3 in patients who previously had CD4 counts < 100-200 cells/mm 3 [16] . Hence patients in our study with baseline CD4 counts < 200 cells/mm 3 , which increased to > 200 cells/mm 3 at first follow-up following HAART initiation, were defined as having IRIS.
Results
A total of 220 consecutive males with HIV were screened, of which 115 who fulfilled all criteria and gave consent underwent hormonal and DEXA analysis ( Figure 1 ). In addition, 40 healthy age-, sex-, and BMI-matched controls underwent the same set of investigations. The median age of our patients with HIV infection was 40 years, having median disease duration of 38 months, with 90.43% on HAART, 35.65% having history of tuberculosis, 51.3% having history of IRIS, and 93.05% patients having vitamin-D deficiency/ /insufficiency (Table I) . Males with HIV had significantly lower BMD and corresponding Z-scores at all the sites evaluated (LS, TF, NOF, greater trochanter, radius total, radius UD, and radius 33%), as compared to controls (Table II) . Osteoporosis involving at least any one site was observed in 74 (64.35%) males with HIV as compared to six (15.00%) individuals in the control group (P < 0.001). The most common site of osteoporosis among HIV-infected males was radius total (49.56%; n = 57), followed by radius 33% (45.21%; n = 52), radius UD ( (Table II) . Patients with HIV had significantly lower total fat mass (P < 0.001), LM (P = 0.024), total fat percentage (P < 0.001), BMC (P = 0.039), gynoid fat (P < 0.001), and PSMM (P = 0.05), as compared to controls (Table II) . Among males with HIV, those with osteoporosis had higher use of HAART (P = 0.007), higher history of IRIS (P = 0.049) and tuberculosis (P = 0.056; approached statistical significance), and lower FM (P = 0.006), LM (P = 0.012), and PSMM (P = 0.004) (Table III) . Binary logistic regression analysis revealed that PSMM, age, and delta (Δ) CD4 count (change in CD4 count at 6-12-month follow-up with regard to CD4 cell count at diagnosis) were consistently the best predictors of occurrence of osteoporosis. A greater PSMM was associated with decreased osteoporosis risk, without adjusting for any variable (Model 1), after adjusting for disease duration, history of tuberculosis, and IRIS (Model 2), and after adjusting for variables in Model 2 plus LH, FSH, oestradiol, and testosterone (Model 3) (Table IV) . A greater increment in CD4 count (Δ CD4 count) was associated with increased risk of osteoporosis after adjusting for Model 1 and Model 3. Increased age was associated with increased risk of osteoporosis after adjusting for variables in Model 2 and 3 (Table IV) .
PSMM in controls and males with HIV was 67.08 ± 4.11% and 63.74 ± 10.66%, respectively (P = 0.05). PSMM < 58.86% (2 SD lower than the mean in controls) was defined as sarcopaenia (vide supra) [11] . Using this definition, sarcopaenia was observed in 46 males (40%) with HIV infection but in none of the control individuals. 35 out of 74 HIV males with osteoporosis (47.29%) had sarcopaenia, in contrast to 11 out of 41 males without osteoporosis (26.83%) (P = 0.029). 64.35% of patients in the HIV group (n = 115) had osteoporosis, in contrast to 15% in the control group (n = 40). This evaluation achieved > 99.9% power, keeping type-I error (alpha) at 5%.
Discussion
Bone mineral (BM) loss in HIV is multifactorial. Immune dysregulation and systemic inflammation (increased circulating levels of cytokines viz. tumour necrosis factor alpha and interleukins, among others) play a role in increased receptor activator of nuclear factor kappa B (RANK) ligand secretion from osteoblasts, along with increased RANK expression on osteoclasts, leading to osteoclast activation and suppression of osteoblasts [17] . HIV viral proteins (vpr and gp120) promote osteoclast activity, and p55-gag suppresses osteoblast activity, in-vitro [18] . Malnutrition, underweight, physical inactivity, malabsorption, hypogonadism, glucocorticoids, vitamin-D deficiency, substance abuse, and smoking all contribute to BM loss in HIV [17] . The HIV-infected patients in our study had a high prevalence of vitamin-D deficiency/insufficiency, reflective of high vitamin-D deficiency state in the BMD and sarcopaenia in HIV Deep Dutta et al.
general population [19, 20] . Vitamin-D deficiency, as well as its classical role in calcium absorption and bone formation, has been linked with increased systemic inflammation, immune dysfunction, autoimmunity, and secondary hyperparathyroidism, which may further accentuate bone loss [21, 22] . In an abstract presented at the 2014 annual conference of the International AIDS Society (the only previous report from India), Dravid et al. reported 29.6% and 36.6%, respectively, HAART naïve (n = 40) and on HAART patients (n = 496) to have osteoporosis [23] . However, details from that study are not available. In contrast, the burden of osteoporosis (at any one site) among young men with HIV is much higher (64.35% patients) in our study, predominantly involving the wrists (36-49%), and much lower at the spine and hip (7-19%) . The high prevalence of vitamin-D may contribute to the increased bone loss at wrists observed in our study (due to associated secondary hyperparathyroidism, which is well known to predominantly effect the peripheral/wrist BMD) [2] . However, serum intact parathyroid hormone levels were not evaluated in this study, which is a limitation.
Our study demonstrated that decreased skeletal mass (PSMM) was the strongest and best predictor of osteoporosis in males with HIV. Skeletal mass is the predominant component of lean mass in the body, which results in more mechanical loading of the body, thus having a positive impact on bone mass [24, 25] . Skeletal muscles in addition cause dynamic loading of the muscles. Bone adapts more to dynamic muscle load than to static load, explaining the stronger effect of skeletal mass (lean mass) over BMD, as compared to fat mass [26] . This also explains the beneficial effect of physical activity on bone health, which is associated with better skeletal mass, and decreased falls, thus deceasing fracture risk [25, 26] . Sarcopaenia is a measure of decreased muscular volume and function. Sarcopaenia was observed in 40% of males with HIV infection but in none of the controls individuals, which further highlights the link between muscle mass and bone mineral loss. Poor nutrition, increased systemic inflammation, hormonal alterations, and neuromuscular and mitochondrial dysfunction (myopathy, polyneuropathy, wasting syndrome) are some of the factors responsible for sarcopenia in HIV [27] [28] [29] [30] [31] [32] . A study in males with HIV infection from Cleveland, USA also documented a high prevalence of low BMD (68.2%) and sarcopaenia (21.9%) [33] . In that study, loss of LM was seen, with an accompanying increase in central fat accumulation and peripheral fat atrophy in HIV patients, as compared to controls [33] . The term, "sarco-osteoporosis" is increasingly being used to highlight the impact of the neuromuscular system on bone health and osteoporotic fractures [34, 35] .
After PSMM, ΔCD4 cell count (change in CD4 cell count at 6-12 months after HAART initiation with regards to pre-HAART CD4 cell count levels) was ; all discreet variables have been expressed as absolute numbers (percentage); anot normally distributed; normality checked using Kolmogorov-Smirnov test; P < 0.05 considered statistically significant; # P-value calculated using Chi-square test;*viral infections include hepatitis-B, hepatitis-C, and others; HAART -highly active anti retro-viral therapy; NRTI -nucleoside reverse transcriptase inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI -protease inhibitors; zidovudine (AZT), lamivudine (3TC), stavudine (d4T), and/or tenofovir (TDF) were the NRTIs received by the patients; nevirapine (NVP) or efavirinez (EFV) were the NNRTIs received by the patients; atazanavir (ATV) or ritonavir (RTV) were the PIs received by the patients; IRIS -immune reconstitution inflammatory syndrome
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consistently the second-best predictor of osteoporosis after adjusting for various variables. A greater ΔCD4 count was associated with increased osteoporosis. A greater ΔCD4 count implies that the patient has a more severe immunodeficiency at the disease onset (lower pre-HAART CD4 count), explaining the greater increase in CD4 count post HAART (better improvement in immune function). Such a CD4 count response is typically associated with higher occurrence of IRIS. Indeed, the occurrence of IRIS was higher in HIV males with osteoporosis as compared to those without osteoporosis in our study. A more severe immunodeficiency at disease 25OHD -25-hydroxy-vitamin-D; ALP -alkaline phosphate; BMD -bone mineral density; L1-L4 -lumbar spine L1 to L4; NOF -neck of femur; PSMMpercentage skeletal muscle mass; osteoporosis defined as Z-score < -2 standard deviation (SD); normality of variable distribution checked using Kolmogorov-Smirnov test; normally distributed variables expressed as mean ± standard deviation; a all non-normally distributed variables expressed as median th percentile]; P-value calculated using unpaired t-test; P < 0.05 considered statistically significant BMD and sarcopaenia in HIV Deep Dutta et al. 
onset, greater ΔCD4 count, and IRIS are associated with higher systemic inflammation, which may contribute to BM loss. Grant PM et al. observed a lower baseline CD4 count to be associated with greater BMD loss in first two years following HAART [31] .
In addition, HAART in general is believed to contribute to osteoporosis [26] . In our study also, patients with osteoporosis had higher use of HAART as compared to those without osteoporosis. HAART is believed to induce marked BMD loss (2-6%) within the first two years, irrespective of antiretroviral agent used [27] . IRIS may have a role in this early HAART-related bone loss [28] . Protease inhibitors and tenofovir have been most commonly linked to BM loss [28] . Tenofovir, through proximal renal tubular toxicity, causes renal phosphate wasting, explaining BM loss [28, 29] . However, in our study, no specific anti-retroviral agent was linked to osteoporosis. Increased age was associated with increased osteoporosis after adjusting for variables in Model 2 and 3. This can be explained by the physiological age-related bone mineral loss in all individuals after the attainment of peak bone mass [2, 8] .
There are limited data on therapeutic outcomes in HIV-associated osteoporosis. Apart from bisphosphonates, no other agent has been evaluated in HIV-associated osteoporosis. Alendronate over a period of 96 weeks has been documented to improve BMD in patients on HAART [36] . In another randomised controlled trial, two annual doses of 4 mg zoledronic acid was demonstrated to have a beneficial effect on BMD, which persisted for at least five years after the second dose [37] .
Limitations of this study include its cross-sectional design. Also, visceral and subcutaneous fat could not be assessed separately because DEXA and not computed tomography was used for body composition analysis. Strengths of this study include the evaluation of a relatively large homogenous cohort of young HIV-infected men, with matched healthy controls, a cohort that has been less evaluated, and one in which bone health assessment would be more meaningful because early therapeutic interventions can improve long-term outcomes.
To conclude, this study highlights the unrecognized significant burden of osteoporosis (64%) and sarcopaenia (40%) in young Indian men with HIV infection. Evaluation of sarcopaenia has an important role in predicting low BMD and osteoporosis in HIV. This study highlights the importance of adequate skeletal mass, and hence daily exercise and physical activity in maintaining bone health. Men with more severe immune dysfunction at diagnosis, who were probably sicker, with lower CD4 counts at diagnosis, and having a more rapid increase in CD4 count following HAART, and having history of IRIS have higher risk of osteoporosis in the long run. 
